Related Experiment Video
Updated: Jan 11, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
18.2K
Pyzchiva (ustekinumab-ttwe): A New Biosimilar for Psoriasis
Bianca Lindecker1, Christopher Giuliano1, Pramodini B Kale-Pradhan1
1Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, Detroit, MI, USA.
The Annals of Pharmacotherapy
|November 14, 2025
Summary
Ustekinumab-ttwe is a biosimilar equivalent to ustekinumab for moderate-to-severe plaque psoriasis. This analysis confirms its comparable pharmacology, efficacy, and safety, offering a new treatment option.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Plaque psoriasis is a chronic inflammatory skin condition.
- Biologics like ustekinumab offer targeted treatment options.
- The development of biosimilars provides alternatives to reference biologics.
Purpose of the Study:
- To evaluate the pharmacology, efficacy, and safety of ustekinumab-ttwe.
- To determine the therapeutic role of ustekinumab-ttwe as a biosimilar for plaque psoriasis.
Main Methods:
- Systematic literature search of PubMed, Embase, and ClinicalTrials.gov.
- Inclusion of studies on pharmacology, pharmacokinetics, efficacy, safety, and immunogenicity.
- Analysis of pharmacokinetic and phase III clinical trial data comparing ustekinumab-ttwe and ustekinumab.
Main Results:
- Pharmacokinetic parameters of ustekinumab-ttwe were similar to reference ustekinumab.
- Phase III trial showed comparable efficacy, with PASI score changes of 85.7% for ustekinumab-ttwe and 86.4% for ustekinumab.
- Ustekinumab-ttwe demonstrated equivalent pharmacology, pharmacokinetics, efficacy, safety, and immunogenicity to ustekinumab.
Conclusions:
- Ustekinumab-ttwe is an equivalent biosimilar to ustekinumab.
- This provides an additional therapeutic option for moderate-to-severe plaque psoriasis.
- Further comparative studies with other ustekinumab biosimilars are not yet available.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
223
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
223
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
470
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
470
01:13Bioequivalence studies: Biowaivers
211
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
211
01:16Bioequivalence: Overview
1.7K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.7K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K